Difference between revisions of "CTSC:education library"
From NAMIC Wiki
| Line 9: | Line 9: | ||
==Biomarkers== | ==Biomarkers== | ||
| + | |||
| + | * Surrogate Endpoints And FDA’s Accelerated Approval Process, Thomas R. Fleming, Heath Affairs, 2005, 24 (1) 67-78 | ||
| + | '''doi''': 10.1377/hlthaff.24.1.67 | ||
| + | |||
| + | == Tumor response == | ||
| + | |||
| + | * New Guidelines to Evaluate the Response to Treatment in Solid Tumors, P. Therasse, Journal of the National Cancer Institute, 2000, 92 (3), 205-216 | ||
| + | * Measurement of Clinical and Subclinical Tumour Response Using [18F]-Fuorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations, H. Young, European Journal of Cancer, 1999, 35 (13), 1773-1782 | ||
Revision as of 18:07, 4 November 2009
Home < CTSC:education libraryBack to Collaboration:Harvard_CTSC
DCE-MRI
- Dynamic contrast enhanced MRI in prostate cancer, Eur. J. Radiol. 2007, 63 (3), 328-334
doi:10.1016/j.ejrad.2007.06.028
Ultrasound
Biomarkers
- Surrogate Endpoints And FDA’s Accelerated Approval Process, Thomas R. Fleming, Heath Affairs, 2005, 24 (1) 67-78
doi: 10.1377/hlthaff.24.1.67
Tumor response
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors, P. Therasse, Journal of the National Cancer Institute, 2000, 92 (3), 205-216
- Measurement of Clinical and Subclinical Tumour Response Using [18F]-Fuorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations, H. Young, European Journal of Cancer, 1999, 35 (13), 1773-1782
